Diagnosis of hepatitis C virus genotype 2k/1b needs NS5B sequencing

International Journal of Infectious Diseases

Volumn 41, Issue , 2015, Pages 1-2

  De Keukeleire, Steven ^a   Descheemaeker, Patrick ^a   Reynders, Marijke ^a  

^a Lab Department of Microbiology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CONTRAST MEDIUM; ETHAMBUTOL; ISONIAZID; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; PYRAZINAMIDE; RIBAVIRIN; RIFAMPICIN; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FATIGUE; FEMALE; GENE SEQUENCE; GRANULOMATOSIS; HEADACHE; HEMATEMESIS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1B; HEPATITIS C VIRUS GENOTYPE 2K; HEPATOSPLENOMEGALY; HUMAN; LABORATORY TEST; LIVER BIOPSY; MALAISE; MALE; MILIARY TUBERCULOSIS; PANCYTOPENIA; SEROLOGY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS STRAIN; AMINO ACID SEQUENCE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HEPACIVIRUS; METABOLISM; PHYSIOLOGY; VIROLOGY;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84946413443     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.10.010     Document Type: Article

References (12)

1. Mondelli M.U., Silini E. Clinical significance of hepatitis C virus genotypes. J Hepatol 1999, 31:65-70.
2. Moreau I., Hegarty S., Levis J., Sheehy P., Crosbie O., Kenny-Walsh E., et al. Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Virol J 2006, 3:95.
3. Raghwani J., Thomas X.V., Koekkoek S.M., Schinkel J., Molenkamp R., van de Laar T.J., et al. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b. J Virol 2012, 86:2212-2220.
4. Morel V., Descamps V., François C., Fournier C., Brochot E., Capron D., et al. Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed hepatitis C infection: a case report. J Clin Virol 2010, 47:383-386.
5. Demetriou V.L., van de Vijver D.A., Cyprus H.C.V., Network, Kostrikis L.G. Molecular epidemiology of hepatitis C infection in Cyprus: evidence of polyphyletic infection. J Med Virol 2009, 81:238-248.
6. Murphy D.G., Willems B., Deschênes M., Hilzenrat N., Mousseau R., Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol 2007, 45:1102-1112.
7. Kalinina O., Norder H., Mukomolov S., Magnius L.O. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 2002, 76:4034-4043.
8. Karchava M., Waldenström J., Parker M., Hallack R., Sharvadze L., Gatserelia L., et al. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: recommendations for testing and treatment. Hepatol Res 2015, 10.1111/hepr.12505.
9. De Keukeleire S., Descheemaeker P., Reynders M. Potential risk of misclassification HCV 2k/1b strains as HCV 2a/2c using VERSANT Genotype 2.0 Assay. Diagn Microbiol Infect Dis 2015, 82:201-202.
10. Kurbanov F., Tanaka Y., Chub E., Maruyama I., Azlarova A., Kamitsukasa H., et al. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. J Infect Dis 2008, 198:1448-1456.
11. Hedskog C., Doehle B., Chodavarapu K., Gontcharova V., Crespo Garcia J., De Knegt R., et al. Characterization of hepatitis C virus inter-genotypic recombinant strains and associated virologic response to sofosbuvir/ribavirin. Hepatology 2015, 61:471-480.
12. Koff R.S. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014, 39:478-487.